Product Name: Human IL-17 Antibody (Secukinumab, Research Use)
Catalog Number: NBR-0441
Target Name: IL-17
Trade Name: Secukinumab
Antibody Drug Description: Secukinumab, sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It inhibits a member of the cytokine family, interleukin 17A. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: IL-17
Synonyms: CTLA8; IL-17; IL-17A; IL17
Target Description: IL17A (Interleukin 17A) is a Protein Coding gene. Diseases associated with IL17A include Allergic Contact Dermatitis and Bronchiolitis Obliterans. Among its related pathways are MIF Mediated Glucocorticoid Regulation and TGF-Beta Pathway. Gene Ontology (GO) annotations related to this gene include cytokine activity. An important paralog of this gene is IL17F.
Ensembl: ENSG00000112115
Uniprot: Q16552